Pluristem Therapeutics Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (27)

Latest Posts

About This Stock More About This Stock
The Bright Future Of Pluristem Therapeutics
Article By: I Know First Research
Monday, February 22, 2016 7:21 AM EDT
On January 14th, PSTI got FDA clearance to begin a phase 1 trial on PLX-R18 cells for the treating incomplete hematopoietic recovery following hematopoietic cell transplantation.
In this article: PSTI
Read
Monday Morning’s Pre-Market Insights: YOKU, QCOM, TEVA, PSTI
Article By: TipRanks
Monday, July 27, 2015 9:12 AM EDT
Teva Pharmaceutical Industries Ltd. shares spiked more than 15% in pre-market trading to $71.36 after the company announced plans to acquire Allergan Generics for $40.5 billion.
In this article: YOKU, QCOM, TEVA, PSTI Also: AGN
Read
Monday Pre-Market Insights: PSTI, JUNO, OSUR, SGYP
Article By: TipRanks
Monday, May 18, 2015 8:59 AM EDT
Monday Pre-Market Insights: PSTI, JUNO, OSUR, SGYP.
In this article: PSTI, JUNO, OSUR, SGYP
Read
AGIO Reports Phase 1/2 Clinical Trial Of AG-221; PSTI Advances Its Second Major Cell Therapy Product Line
Article By: BioMedReports
Wednesday, October 22, 2014 3:24 AM EDT
Agios Pharmaceuticals announced the initiation of a Phase 1/2 multicenter study of AG-221 in patients with advanced solid tumors. Pluristem Therapeutics announced it has completed development of its second major product line.
In this article: PSTI, AGIO
Read
Healthcare Review: ISR, CBMX, THC, PSTI
Article By: BioMedReports
Tuesday, October 7, 2014 3:58 PM EDT
U.S. stock indexes are following other global markets lower in early trading. European stocks fell after Germany reported the biggest monthly drop in industrial production in five years.
In this article: THC, ISR, CBMX, PSTI
Read

PARTNER HEADLINES

Latest Tweets for $PSTI

No tweets yet!